The global P1 and PL1 inhibitors market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing incidence of cancer and rising demand for new drugs in the treatment of cancer. The global P1 and PL1 inhibitors market is segmented on the basis of type, application, and region. On the basis of type, it is classified into K drugs, O drugs, T drugs, B drugs, I drugs; on the basis of application it includes gastric tumor (G), colorectal cancer (CRC), Hodgkin'S lymphoma (HL), no small cell lung cancer (NSCLC), urothelial carcinoma (UC) renal cell carcinoma (RCC) hepatocellular carcinoma(HCC); on the basis of region it includes North America(NA), Latin America(LA), Europe(EU) Asia Pacific & Middle East & Africa(APMEA).
North America dominates this market with a share over 50%. This can be attributed to high prevalence rates for cancers in this region as well as increased awareness about these types of diseases among people living in North America.
-The PD-1 and PD-L1 inhibitors market is expected to grow at a CAGR of around 20% from 2018 to 2025.
-The increasing prevalence of cancer, rising incidence rates, and the growing number of cancer survivors are some factors that are driving the growth of this market.
-The increasing number of clinical trials for these drugs is also driving the growth in this market.
Industry Growth Insights published a new data on “PD-1 and PD-L1 Inhibitors Market”. The research report is titled “PD-1 and PD-L1 Inhibitors Market research by Types (K Drugs, O Drugs, T Drugs, B Drugs, I Drugs), By Applications (Gastric Tumor, Colorectal Cancer, Hodgkin'S Lymphoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatoma, Other), By Players/Companies Merck, Pfizer, Roche, AstraZeneca, Bristol-Myers Squibb, Novartis, Biocad, Tesaro, Johnson & Johnson, Boehringer Ingelheim, CytomX, Shanghai Junshi Biosciences, Jiangsu Hengrui Medicine, Innovent Biologics, Beigene, Genor Biopharma, Zhaoke Pharmaceutical, ALPHAMAB ONCOLOGY, 3D Medicines, Harbin Gloria Pharmaceuticals, WuXi AppTec”.
Scope Of The Report
Report Attributes
Report Details
Report Title
PD-1 and PD-L1 Inhibitors Market Research Report
By Type
K Drugs, O Drugs, T Drugs, B Drugs, I Drugs
By Application
Gastric Tumor, Colorectal Cancer, Hodgkin'S Lymphoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatoma, Other
By Companies
Merck, Pfizer, Roche, AstraZeneca, Bristol-Myers Squibb, Novartis, Biocad, Tesaro, Johnson & Johnson, Boehringer Ingelheim, CytomX, Shanghai Junshi Biosciences, Jiangsu Hengrui Medicine, Innovent Biologics, Beigene, Genor Biopharma, Zhaoke Pharmaceutical, ALPHAMAB ONCOLOGY, 3D Medicines, Harbin Gloria Pharmaceuticals, WuXi AppTec
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global PD-1 and PD-L1 Inhibitors Market Report Segments:
The global PD-1 and PD-L1 Inhibitors market is segmented on the basis of:
Types
K Drugs, O Drugs, T Drugs, B Drugs, I Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gastric Tumor, Colorectal Cancer, Hodgkin'S Lymphoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatoma, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Pfizer
- Roche
- AstraZeneca
- Bristol-Myers Squibb
- Novartis
- Biocad
- Tesaro
- Johnson & Johnson
- Boehringer Ingelheim
- CytomX
- Shanghai Junshi Biosciences
- Jiangsu Hengrui Medicine
- Innovent Biologics
- Beigene
- Genor Biopharma
- Zhaoke Pharmaceutical
- ALPHAMAB ONCOLOGY
- 3D Medicines
- Harbin Gloria Pharmaceuticals
- WuXi AppTec
Highlights of The PD-1 and PD-L1 Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- K Drugs
- O Drugs
- T Drugs
- B Drugs
- I Drugs
- By Application:
- Gastric Tumor
- Colorectal Cancer
- Hodgkin'S Lymphoma
- Non-Small Cell Lung Cancer
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Hepatoma
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the PD-1 and PD-L1 Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PD-1 inhibitors are drugs that block the activity of PD-1. PD-L1 inhibitors work in a similar way, but they specifically target PD-L1.
Some of the major companies in the pd-1 and pd-l1 inhibitors market are Merck, Pfizer, Roche, AstraZeneca, Bristol-Myers Squibb, Novartis, Biocad, Tesaro, Johnson & Johnson, Boehringer Ingelheim, CytomX, Shanghai Junshi Biosciences, Jiangsu Hengrui Medicine, Innovent Biologics, Beigene, Genor Biopharma, Zhaoke Pharmaceutical, ALPHAMAB ONCOLOGY, 3D Medicines, Harbin Gloria Pharmaceuticals, WuXi AppTec.
The pd-1 and pd-l1 inhibitors market is expected to register a CAGR of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. PD-1 and PD-L1 Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. PD-1 and PD-L1 Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. PD-1 and PD-L1 Inhibitors Market - Supply Chain
4.5. Global PD-1 and PD-L1 Inhibitors Market Forecast
4.5.1. PD-1 and PD-L1 Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. PD-1 and PD-L1 Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. PD-1 and PD-L1 Inhibitors Market Absolute $ Opportunity
5. Global PD-1 and PD-L1 Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Type
5.3.1. K Drugs
5.3.2. O Drugs
5.3.3. T Drugs
5.3.4. B Drugs
5.3.5. I Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global PD-1 and PD-L1 Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Application
6.3.1. Gastric Tumor
6.3.2. Colorectal Cancer
6.3.3. Hodgkin'S Lymphoma
6.3.4. Non-Small Cell Lung Cancer
6.3.5. Urothelial Carcinoma
6.3.6. Renal Cell Carcinoma
6.3.7. Hepatoma
6.3.8. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global PD-1 and PD-L1 Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global PD-1 and PD-L1 Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global PD-1 and PD-L1 Inhibitors Demand Share Forecast, 2019-2026
9. North America PD-1 and PD-L1 Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Application
9.4.1. Gastric Tumor
9.4.2. Colorectal Cancer
9.4.3. Hodgkin'S Lymphoma
9.4.4. Non-Small Cell Lung Cancer
9.4.5. Urothelial Carcinoma
9.4.6. Renal Cell Carcinoma
9.4.7. Hepatoma
9.4.8. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Type
9.7.1. K Drugs
9.7.2. O Drugs
9.7.3. T Drugs
9.7.4. B Drugs
9.7.5. I Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America PD-1 and PD-L1 Inhibitors Demand Share Forecast, 2019-2026
10. Latin America PD-1 and PD-L1 Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Application
10.4.1. Gastric Tumor
10.4.2. Colorectal Cancer
10.4.3. Hodgkin'S Lymphoma
10.4.4. Non-Small Cell Lung Cancer
10.4.5. Urothelial Carcinoma
10.4.6. Renal Cell Carcinoma
10.4.7. Hepatoma
10.4.8. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Type
10.7.1. K Drugs
10.7.2. O Drugs
10.7.3. T Drugs
10.7.4. B Drugs
10.7.5. I Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America PD-1 and PD-L1 Inhibitors Demand Share Forecast, 2019-2026
11. Europe PD-1 and PD-L1 Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Application
11.4.1. Gastric Tumor
11.4.2. Colorectal Cancer
11.4.3. Hodgkin'S Lymphoma
11.4.4. Non-Small Cell Lung Cancer
11.4.5. Urothelial Carcinoma
11.4.6. Renal Cell Carcinoma
11.4.7. Hepatoma
11.4.8. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Type
11.7.1. K Drugs
11.7.2. O Drugs
11.7.3. T Drugs
11.7.4. B Drugs
11.7.5. I Drugs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe PD-1 and PD-L1 Inhibitors Demand Share, 2019-2026
12. Asia Pacific PD-1 and PD-L1 Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Application
12.4.1. Gastric Tumor
12.4.2. Colorectal Cancer
12.4.3. Hodgkin'S Lymphoma
12.4.4. Non-Small Cell Lung Cancer
12.4.5. Urothelial Carcinoma
12.4.6. Renal Cell Carcinoma
12.4.7. Hepatoma
12.4.8. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Type
12.7.1. K Drugs
12.7.2. O Drugs
12.7.3. T Drugs
12.7.4. B Drugs
12.7.5. I Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific PD-1 and PD-L1 Inhibitors Demand Share, 2019-2026
13. Middle East & Africa PD-1 and PD-L1 Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Application
13.4.1. Gastric Tumor
13.4.2. Colorectal Cancer
13.4.3. Hodgkin'S Lymphoma
13.4.4. Non-Small Cell Lung Cancer
13.4.5. Urothelial Carcinoma
13.4.6. Renal Cell Carcinoma
13.4.7. Hepatoma
13.4.8. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa PD-1 and PD-L1 Inhibitors Market Size and Volume Forecast by Type
13.7.1. K Drugs
13.7.2. O Drugs
13.7.3. T Drugs
13.7.4. B Drugs
13.7.5. I Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa PD-1 and PD-L1 Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global PD-1 and PD-L1 Inhibitors Market: Market Share Analysis
14.2. PD-1 and PD-L1 Inhibitors Distributors and Customers
14.3. PD-1 and PD-L1 Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bristol-Myers Squibb
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Biocad
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Tesaro
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Johnson & Johnson
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Boehringer Ingelheim
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. CytomX
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Shanghai Junshi Biosciences
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Jiangsu Hengrui Medicine
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Innovent Biologics
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Beigene
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Genor Biopharma
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Zhaoke Pharmaceutical
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. ALPHAMAB ONCOLOGY
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. 3D Medicines
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
